A Case of Epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculosis infection

Risultato della ricerca: Article

8 Citazioni (Scopus)

Abstract

Background: Intravesical instillation of bacille Calmette-Guérin (BCG) has been established as efficient therapy for superficial bladder carcinoma. Overall, intravesical BCG is well tolerated and results in complications of less than 5 %. However, adverse effects such as granulomatous prostatitis, pneumonitis, hepatitis, sepsis, and hypersensitivity reactions may occur. The reported rate for tuberculous orchitis after BCG intravesical therapy is 0.4 %. Findings: We report a case of monolateral tuberculous orchitis occurring one month after the second course of intravescical instillation of bacille Calmette-Guérin in a patient with proven superficial bladder carcinoma and latent tuberculosis infection. Conclusions: In our opinion intravesical instillation of BCG should be considered on an individual patient basis, with full patient disclosure of the potentially significant risks. A screening with an intradermal Mantoux before starting the first cycle of BCG instillation should be recommended and isoniazid would be indicated as the treatment for latent tuberculosis infection.
Lingua originaleEnglish
pagine (da-a)25-27
Numero di pagine3
RivistaInfectious Agents and Cancer
Volume11
Stato di pubblicazionePublished - 2016

Fingerprint

Orchitis
Latent Tuberculosis
Intravesical Administration
Urinary Bladder
Carcinoma
Prostatitis
Isoniazid
Disclosure
Hepatitis
Sepsis
Pneumonia
Hypersensitivity
Therapeutics

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Infectious Diseases
  • Cancer Research
  • Oncology

Cita questo

@article{efa7ad2a454d46c0841b6af1fb09ecaa,
title = "A Case of Epididymo-orchitis after intravesical bacille Calmette-Gu{\'e}rin therapy for superficial bladder carcinoma in a patient with latent tuberculosis infection",
abstract = "Background: Intravesical instillation of bacille Calmette-Gu{\'e}rin (BCG) has been established as efficient therapy for superficial bladder carcinoma. Overall, intravesical BCG is well tolerated and results in complications of less than 5 {\%}. However, adverse effects such as granulomatous prostatitis, pneumonitis, hepatitis, sepsis, and hypersensitivity reactions may occur. The reported rate for tuberculous orchitis after BCG intravesical therapy is 0.4 {\%}. Findings: We report a case of monolateral tuberculous orchitis occurring one month after the second course of intravescical instillation of bacille Calmette-Gu{\'e}rin in a patient with proven superficial bladder carcinoma and latent tuberculosis infection. Conclusions: In our opinion intravesical instillation of BCG should be considered on an individual patient basis, with full patient disclosure of the potentially significant risks. A screening with an intradermal Mantoux before starting the first cycle of BCG instillation should be recommended and isoniazid would be indicated as the treatment for latent tuberculosis infection.",
keywords = "Bladder; Calmette; Complications; Gu{\'e}rin; Intravesical; Infectious Diseases; Oncology; Epidemiology; Cancer Research",
author = "Claudia Colomba and {Di Carlo}, Paola and Lucia Siracusa and Marcello Trizzino and Giuliana Guadagnino and Claudia Gioe'",
year = "2016",
language = "English",
volume = "11",
pages = "25--27",
journal = "Infectious Agents and Cancer",
issn = "1750-9378",
publisher = "BioMed Central",

}

TY - JOUR

T1 - A Case of Epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculosis infection

AU - Colomba, Claudia

AU - Di Carlo, Paola

AU - Siracusa, Lucia

AU - Trizzino, Marcello

AU - Guadagnino, Giuliana

AU - Gioe', Claudia

PY - 2016

Y1 - 2016

N2 - Background: Intravesical instillation of bacille Calmette-Guérin (BCG) has been established as efficient therapy for superficial bladder carcinoma. Overall, intravesical BCG is well tolerated and results in complications of less than 5 %. However, adverse effects such as granulomatous prostatitis, pneumonitis, hepatitis, sepsis, and hypersensitivity reactions may occur. The reported rate for tuberculous orchitis after BCG intravesical therapy is 0.4 %. Findings: We report a case of monolateral tuberculous orchitis occurring one month after the second course of intravescical instillation of bacille Calmette-Guérin in a patient with proven superficial bladder carcinoma and latent tuberculosis infection. Conclusions: In our opinion intravesical instillation of BCG should be considered on an individual patient basis, with full patient disclosure of the potentially significant risks. A screening with an intradermal Mantoux before starting the first cycle of BCG instillation should be recommended and isoniazid would be indicated as the treatment for latent tuberculosis infection.

AB - Background: Intravesical instillation of bacille Calmette-Guérin (BCG) has been established as efficient therapy for superficial bladder carcinoma. Overall, intravesical BCG is well tolerated and results in complications of less than 5 %. However, adverse effects such as granulomatous prostatitis, pneumonitis, hepatitis, sepsis, and hypersensitivity reactions may occur. The reported rate for tuberculous orchitis after BCG intravesical therapy is 0.4 %. Findings: We report a case of monolateral tuberculous orchitis occurring one month after the second course of intravescical instillation of bacille Calmette-Guérin in a patient with proven superficial bladder carcinoma and latent tuberculosis infection. Conclusions: In our opinion intravesical instillation of BCG should be considered on an individual patient basis, with full patient disclosure of the potentially significant risks. A screening with an intradermal Mantoux before starting the first cycle of BCG instillation should be recommended and isoniazid would be indicated as the treatment for latent tuberculosis infection.

KW - Bladder; Calmette; Complications; Guérin; Intravesical; Infectious Diseases; Oncology; Epidemiology; Cancer Research

UR - http://hdl.handle.net/10447/192939

UR - http://www.infectagentscancer.com/

M3 - Article

VL - 11

SP - 25

EP - 27

JO - Infectious Agents and Cancer

JF - Infectious Agents and Cancer

SN - 1750-9378

ER -